Enlivex Therapeutics Ltd. (ENLV): Price and Financial Metrics
GET POWR RATINGS... FREE!
ENLV Stock Price Chart Interactive Chart >
ENLV Price/Volume Stats
| Current price | $4.72 | 52-week high | $13.95 |
| Prev. close | $4.35 | 52-week low | $3.65 |
| Day low | $4.37 | Volume | 49,900 |
| Day high | $4.77 | Avg. volume | 70,392 |
| 50-day MA | $5.51 | Dividend yield | N/A |
| 200-day MA | $7.18 | Market Cap | 86.72M |
Enlivex Therapeutics Ltd. (ENLV) Company Bio
Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patients. The company is also developing Allocetra for the prevention of complications associated with bone marrow transplantations and/or HSCT, and acute multiple organ failure. It also intends to develop its cell-based therapy to be combined with treatments of solid tumors via immune checkpoint rebalancing to enhance the efficacy of various anti-cancer therapies, including chimeric antigen receptor T-Cell therapy and therapies targeting T-Cell receptor therapy. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
Latest ENLV News From Around the Web
Below are the latest news stories about Enlivex Therapeutics Ltd that investors may wish to consider to help them evaluate ENLV as an investment opportunity.
Enlivex to Detail the Application of its Innovative Macrophage Reprogramming Cell Therapy to Unmet Needs in Oncology at the 11th Annual LifeSci Partners Corporate Access Event** Management to participate in a panel discussion: “Innovative Approaches to Cell Therapy for Oncology,” which is taking place on Friday, January 7th, at 8:30 AM ET ** ** Panelists to discuss how their cell-based technologies, including, CAR-T cells, CAR-NK cells, TCR-T cells, and macrophage reprogramming, may address unmet needs in oncology ** Nes-Ziona, Israel, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming |
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining... |
Enlivex Therapeutics (ENLV) Gets a Buy Rating from H.C. WainwrightH.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Enlivex Therapeutics (ENLV – Research Report) today and set a price target of $33.00. The company's shares closed last Monday at $6.61, close to its 52-week low of $6.20. According to TipRanks.com, Selvaraju 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.7% and a 21.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Aquestive Therapeutics, and Inovio Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Enlivex Therapeutics with a $33.00 average price target. |
10 Micro-Cap Stocks to Buy According to Cathie WoodIn this article, we discuss the 10 micro-cap stocks to buy according to Cathie Wood. If you want to skip our detailed analysis of Cathie Wood’s investment philosophy and hedge fund performance, go directly to the 5 Micro-Cap Stocks to Buy According to Cathie Wood. Cathie Wood, the ARK Investment Management CEO, has been known […] |
Enlivex Receives Regulatory Authorization to Expand its Phase IIb Trial Evaluating Allocetra in Severe and Critical COVID-19 Patients into GreeceNes-Ziona, Israel, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the Company’s preclinical and clinical data, study design, and manufacturing process, Greece’s National Organization of Medicines has authorized the expansion of the Company's Phase IIb trial evaluating AllocetraTM in severe and critical COVID-19 patients with acute respiratory di |
ENLV Price Returns
| 1-mo | -18.76% |
| 3-mo | -7.99% |
| 6-mo | -34.72% |
| 1-year | -49.63% |
| 3-year | -58.78% |
| 5-year | -73.78% |
| YTD | -24.48% |
| 2021 | -25.86% |
| 2020 | 0.46% |
| 2019 | 36.22% |
| 2018 | -66.38% |
| 2017 | -55.96% |
Loading social stream, please wait...